Podcasts about Gilead

Name of three people and two geographical locations in the Bible

  • 1,689PODCASTS
  • 4,751EPISODES
  • 32mAVG DURATION
  • 2DAILY NEW EPISODES
  • Jan 30, 2025LATEST
Gilead

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about Gilead

Show all podcasts related to gilead

Latest podcast episodes about Gilead

ESC TV Today – Your Cardiovascular News
Episode 8: DAPT in 2025 - Optimal communication with patients

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Jan 30, 2025 24:09


This episode covers: Cardiology This Week: A concise summary of recent studies Dual antiplatelet therapy in 2025 Optimal communication with patients Snapshots Host: Emer Joyce  Guests: Carlos Aguiar, Michelle Kittleson, Gilles Montalescot Want to watch that episode? Go to: https://esc365.escardio.org/event/1798   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Emer Joyce, Michelle Kittleson and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Gilles Montalescot has declared to have potential conflicts of interest to report: research funds for Action Groupe or honoraria from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today – Your Cardiovascular News
Episode 8: Extended interview on dual antiplatelet therapy in 2025

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Jan 30, 2025 14:42


Host: Emer Joyce Guest: Gilles Montalescot Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1798?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Gilles Montalescot has declared to have potential conflicts of interest to report: research funds for Action Groupe or honoraria from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Dear Cancer, I'm Beautiful
“SABCS 2024 Highlights Made Simple” with Dr. Tiffany Troso

Dear Cancer, I'm Beautiful

Play Episode Listen Later Jan 22, 2025 53:58


In this episode, I'm thrilled to welcome Dr. Tiffany Troso, a medical oncologist with over 25 years of experience in treating breast and gynecological cancers. We'll unpack some of the most important updates from this year's San Antonio Breast Cancer Symposium (SABCS) in a way that's clear and easy to follow. We'll cover topics like the latest on SERDS and how they're changing treatment options, the practice-changing findings from the PATINA trial, and exciting progress on a TNBC vaccine. Dr. Troso also sheds light on the growing movement toward treatment de-escalation and what it means for creating more personalized approaches to care. This episode is packed with valuable information to help patients and advocates feel informed and prepared to navigate their health journey. A special thank you to our “Your Guide to SABCS sponsors” Lilly, Gilead, Merck, Daiichi-Sankyo and Pfizer for making this episode possible.

Lancefield on the Line
Dina Denham Smith: Leading with your emotions

Lancefield on the Line

Play Episode Listen Later Jan 22, 2025 42:14


Are emotions at work a sign of weakness?This is the view of many, but understanding and harnessing our emotions, and the emotions of others around us can be incredibly powerful.In this episode I am joined by Dina Denham Smith, to argue the case for a skilful use of emotions at work. Dina is the co-author of Emotionally Charged, where she explores how to lead with the strategic use of emotions.We address common myths about emotions in the workplace and how you can prepare for and recover from emotionally charged events. Dina also discusses the importance of a nuanced approach to using your emotions as a leader, and how self-compassion towards yourself can lead to unlocking self-compassion in others.Dina provides lots of nuggets of wisdom in this masterclass on emotions.“Emotions are data, and to ignore this information is to your peril and performance detriment.” – Dina SmithYou'll hear about:Understanding the application of emotions in businessDina's thoughts on not showing emotionsHow to use emotions skilfullyPreparing for emotionally charged eventsRecovering from emotionally charged eventsDealing with over-emotional situationsHaving a nuanced approach to emotionsHow to be strategic with your emotionsThe biggest change Dina has made to her practiceWhat does Dina's best day look like?The impact Dina wants to have on the world About Dina Denham:Dina is a seasoned leader and executive coach with a 25-year proven track record in helping people and teams excel. Dina's clients include senior leaders and teams at premier brands such as Adobe, PwC, Gilead, Gap, Sephora, Goldman Sachs, Google, and Netflix; high-growth companies like Dropbox, DocuSign, and Stripe; and PE-backed start-ups shaping the world. Dina has written over 60 articles on leadership and career success for the Harvard Business Review, Fast Company, and Forbes and is frequently featured in international media outlets such as the Wall Street Journal, Newsweek, Business Insider, and the BBC. She is the lead author of Emotionally Charged: How to Lead in the New World of Work (Oxford Press).An East Coast transplant, Dina now lives in the SF Bay Area with her husband, kids, and two spoiled pups. Outside of work, she is a competitive equestrian, avid skier and reader, foodie, and travel enthusiast.Resources:• Profile: https://www.linkedin.com/in/dina-denham-smith/• Book: ‘Emotionally charged: how to lead in the new world of work', https://www.dinadsmith.com/book• Coaching services: https://www.dinadsmith.com/coachingMy resources:Take my new Becoming a Strategic Leader course (https://bit.ly/3KJYDTj)Sign up to my Every Day is a Strategy Day newsletter (http://bit.ly/36WRpri) for modern mindsets and practices to help you get ahead.Subscribe to my YouTube channel (http://bit.ly/3cFGk1k) where you can watch the conversation.For more details about me:● Services (https://rb.gy/ahlcuy) to CEOs, entrepreneurs and professionals.● About me (https://rb.gy/dvmg9n) - my background, experience and philosophy.● Examples of my writing https://rb.gy/jlbdds)● Follow me and engage with me on LinkedIn (https://bit.ly/2Z2PexP)● Follow me and engage with me on Twitter (https://bit.ly/36XavNI)

ACEP Frontline - Emergency Medicine
Bonus Bytes - Gilead FOCUS Program

ACEP Frontline - Emergency Medicine

Play Episode Listen Later Jan 19, 2025 9:42


In this track, we talk with the Gilead FOCUS team and their effort to improve blood borne pathogen screening in the emergency department. https://www.gilead.com/responsibility/global-health-and-access/focus

IRLAF: In Real Life Adult Friendship
Every Story is a God Story

IRLAF: In Real Life Adult Friendship

Play Episode Listen Later Jan 16, 2025 13:56


This week's sermon is a little different, because in it, Rebecca addresses the heartbreaking decision to end Gilead. I attended service in person for this sermon, and I gotta say, I'm glad I was there. But for those of you who weren't, or for those of you who would just like to listen again, here it is.  After a vote by the congregation to close the church during the service this past Sunday, Gilead will officially be ending. And as hard and as sad as it was to come to this decision, we're trying not to get too sad yet because we will continue with services and celebrations and storytelling until at least Easter of this year. So, we have that to look forward to. It's not the end quite yet.  SUPPORT As we continue to have services and celebrations so that we can close Gilead with celebration and joy, we still could always use your support. You can support us⁠⁠⁠⁠⁠⁠ ⁠here on our website⁠⁠⁠⁠⁠⁠⁠. Any and all donations will go towards providing an incredible final chapter to our congregants and listeners before we close this spring. JOIN US IRL! Whoever you are, whatever your story is, you are welcome with us.⁠⁠⁠⁠⁠⁠ ⁠Sign up for our newsletter here⁠⁠⁠⁠⁠⁠⁠ to stay up to date on when and where our services are happening! (Sometimes that info changes, so the newsletter is the best way to keep up.) ABOUT US Just to make sure this is clear, we'd like to reiterate that everyone is welcome at our church. EVERYONE. We believe that human diversity of race, ethnicity, sexual orientation, gender identity, and gender expression — not to mention age, ability, relationship status, size — is necessary to reflect the fullness of God. Whoever you are, whatever your story is, you are welcome here.  *** This episode was recorded during our service on January 12, 2025.

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.7: Extended interview on coronary spam

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Jan 16, 2025 10:49


Host: Emer Joyce Guest: Filippo Crea Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1797?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Filippo Crea, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today – Your Cardiovascular News
Season 3 - Ep.7: Coronary spasm - Sex differences in heart failure

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Jan 16, 2025 23:42


This episode covers: Cardiology This Week: A concise summary of recent studies Coronary spasm management Sex differences in heart failure Milestones: London Bus Driver Host: Emer Joyce Guests: Filippo Crea, Lynne Stevenson Want to watch that episode? Go to: https://esc365.escardio.org/event/1797 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Filippo Crea, Emer Joyce, Nicolle Kraenkel and Lynne Stevenson have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Pharma and BioTech Daily
Pharma and Biotech Daily: JPM25 Recap and Industry Updates

Pharma and BioTech Daily

Play Episode Listen Later Jan 16, 2025 1:43


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eli Lilly projects a revenue miss for 2024 due to lower-than-anticipated sales of glp-1 blockbusters Mounjaro and Zepbound, causing their shares to drop by as much as 8%. Despite pressure to make a deal, Biogen executives refuse to do so out of desperation. The JPM25 conference featured presentations from Roche, Amgen, Merck, Lilly, and Biogen detailing their growth strategies. Keros fully terminates a mid-stage study on pulmonary arterial hypertension, potentially facing challenges ahead. AGC Biologics offers scale-down data for gene of interest candidates to accelerate timelines. Other news includes questions about accelerated approval for Biogen and Sarepta drugs, lessons learned from Neuropsych's stumbles, and increased drug prices by pharmacy benefit managers. Additionally, Lykos loses board directors after an FDA rejection, while biopharma deals start flowing at JPM25.Biogen executives, despite investor and analyst pressure, are not desperate to make a deal at JPM25. The biopharma industry saw a flood of deals at the event, with companies like Eli Lilly, GSK, and Gilead announcing billion-dollar deals. Seaport is learning from Neuropsych's mistakes amidst renewed interest in the field. The top VC raises in biotech for 2024 were highlighted, showing a significant increase in funding for the industry. J&J made a major neuro play with a $14.6 billion buyout, while Biogen submitted an offer to buy partner Sage. Overall, the industry sentiment has been reinvigorated by the flurry of deals at JPM25.

Pharma and BioTech Daily
Pharma and Biotech Daily: Unpacking the Latest from J.P. Morgan Healthcare Conference

Pharma and BioTech Daily

Play Episode Listen Later Jan 15, 2025 0:37


Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma & Biotech world.The J.P. Morgan Healthcare Conference saw a surge in biopharma deals, with companies like Eli Lilly, GSK, and Gilead announcing billion-dollar deals. Pfizer and Kailera Therapeutics presented updates on obesity treatments, while Biogen and Eisai are seeking FDA approval for new formulations of an anti-amyloid antibody. Other news includes Regeneron's success in a phase III skin cancer trial and Lilly's acquisition of a new molecule. The industry sentiment has been boosted by the flurry of deals at the conference.

BioSpace
Dispatches From JPM, Biogen's Sage Buyout Offer, Pfizer's Obesity Play, More

BioSpace

Play Episode Listen Later Jan 15, 2025 12:13


The J.P. Morgan Healthcare Conference kicked off Monday with a flood of high-value deals, reinvigorating sentiment across the biopharma industry. Johnson & Johnson made the biggest splash, acquiring neurology leader Intra-Cellular Therapies for $14.6 billion, while GSK picked up precision therapy specialist IDRx for $1B upfront and Eli Lilly laid down up to $2.5 billion for Scorpion's PI3Kα inhibitor program. Meanwhile, the immunology and inflammation space continues to fire on all cylinders as Gilead invests up to $1.7 billion for LEO Pharma's preclinical oral small molecule STAT6 program. And those are only the deals accepted by both parties. Prior to the conference, Biogen offered to acquire its struggling neuro partner Sage Therapeutics for around $469M. The proposal follows a catastrophic run for Sage, which has seen its shares fall more than 90% in the past two years. 2024 sales and earnings forecasts have also generated attention this week, with Sarepta reporting that Duchenne muscular dystrophy gene therapy Elevidys beat analysts' expectations in the fourth quarter, and Eli Lilly projecting a full-year revenue miss driven largely by lower-than-expected sales of GLP-1 blockbusters Zepbound and Mounjaro. As expected, obesity has been a hot topic at JPM, with Pfizer CEO Albert Bourla announcing that his company is going “all in” in the space. This follows new FDA guidance revealed last week recommending a minimum weight loss threshold for drug developers. Among the many companies taking notice is newcomer Verdiva Bio, which launched last week with more than $410 million in opening funds. Also debuting last week was Kardigan, which raised $300 million to tackle heart disease. Kadigan joins a resurgent cardiovascular space, where several companies—including those developing gene therapies—are targeting myriad diseases. Finally, BioSpace senior editor Annalee Armstrong caught up with Daphne Zohar, CEO of BioSpace NextGen 2025 company Seaport Therapeutics Daphne Zohar, who offered her thoughts on the current state of the neuropsychiatric space.

Audio Bible Old Testament Genesis to Job King James Version
1 Kings (3 Kings) 22: And they continued three years without war between Syria and Israel. ...

Audio Bible Old Testament Genesis to Job King James Version

Play Episode Listen Later Jan 15, 2025 5:00


église AB Lausanne ; KJV 1 Kings (3 Kings) 22 And they continued three years without war between Syria and Israel. And it came to pass in the third year, that Jehoshaphat the king of Judah came down to the king of Israel. And the king of Israel said unto his servants, Know ye that Ramoth in Gilead is ours, and we be still, and take it not out of the hand of the king of Syria? And he said unto Jehoshaphat, Wilt thou go with me to battle to Ramoth-gilead? And Jehoshaphat said to the king of Israel, I am as thou art, my people as thy people, my horses as thy horses. And Jehoshaphat said unto the king of Israel, Inquire, I pray thee, at the word of the LORD to day. Then the king of Israel gathered the prophets together, about four hundred men, and said unto them, Shall I go against Ramoth-gilead to battle, or shall I forbear? And they said, Go up; for the Lord shall deliver it into the hand of the king. And Jehoshaphat said, Is there not here a prophet of the LORD besides, that we might inquire of him? And the king of Israel said unto Jehoshaphat, There is yet one man, Micaiah the son of Imlah, by whom we may inquire of the LORD: but I hate him; for he doth not prophesy good concerning me, but evil. And Jehoshaphat said, Let not the king say so. Then the king of Israel called an officer, and said, Hasten hither Micaiah the son of Imlah. And the king of Israel and Jehoshaphat the king of Judah sat each on his throne, having put on their robes, in a void place in the entrance of the gate of Samaria; and all the prophets prophesied before them. ...

Pharma and BioTech Daily
Pharma and Biotech Daily: The Latest in Acquisitions, Regulatory News, and Innovative Therapies

Pharma and BioTech Daily

Play Episode Listen Later Jan 14, 2025 2:10


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Johnson & Johnson has made a significant move in the neurology field by acquiring Intra-Cellular for $14.6 billion, gaining access to assets such as Caplyta for schizophrenia and bipolar depression. Biogen has submitted an offer to acquire Sage Therapeutics after facing regulatory and clinical challenges. Gilead is diversifying with a potential $1.7 billion inflammation pact with Leo, focusing on targeting stat6. The FDA's evolving biomarker focus was highlighted by a committee's decision to limit the use of Keytruda and Opdivo in certain cancers based on PD-L1 expression levels. AGC Biologics is offering representative scale-down data for gene of interest candidates before committing to a GMP contract, potentially accelerating timelines by up to 6 months. Other news includes GSK's acquisition of Idorsia targeting rare cancer, AbbVie absorbing the cost of a schizophrenia failure, and collaborations between Merus and Biohaven. Additionally, five novel FDA approvals have been achieved in 2024, while Passage Bio is cutting staff to extend cash runway.The FDA's evolving focus on biomarkers is reflected in the scrutiny of Keytruda and Opdivo for stomach and esophageal cancers based on PD-L1 expression levels. This trend leverages ever-maturing datasets to make more informed decisions about drug approvals. In addition, five novel FDA approvals in 2024 included new mechanisms of action in oncology and neurosciences. Gene therapies for cardiovascular diseases like congestive heart failure and cardiomyopathy are advancing in the clinic, benefiting from technological advancements and positive early data. The NextGen Class of 2025 startups are focusing on ADCs, radiopharmaceuticals, and cell and gene therapies. Pfizer's subcutaneous PD-1 blocker showed positive results in bladder cancer trials, while Denali and AbbVie/Calico faced setbacks in ALS trials. The FDA is proposing setting a bar for weight-loss therapies as the obesity space heats up, with Metsera touting powerful weight loss results.

In the Word
The Life of the Prophet Elijah - An Ordinary Man - Lesson 1

In the Word

Play Episode Listen Later Jan 12, 2025 27:38


Lesson 1 - An Ordinary Man1 Kings 17:1-15.We know nothing about the Prophet Elijah other than he came from the town of Tishbe in Gilead. No one knows about his family or his education, all we do know is that he was rather an odd character! But his life teaches us that God knows how to raise up leaders when they are needed, and that He can use anyone — even a person from absolute obscurity — to do His will!

Audio Bible Old Testament Genesis to Job King James Version
1 Kings (3 Kings) 17: And Elijah the Tishbite, who was of the inhabitants of Gilead, said unto Ahab, As the LORD God of Israel liveth, before whom I stand, there shall not be dew nor rain these years, but according to my word. ...

Audio Bible Old Testament Genesis to Job King James Version

Play Episode Listen Later Jan 10, 2025 5:00


église AB Lausanne ; KJV 1 Kings (3 Kings) 17 And Elijah the Tishbite, who was of the inhabitants of Gilead, said unto Ahab, As the LORD God of Israel liveth, before whom I stand, there shall not be dew nor rain these years, but according to my word. And the word of the LORD came unto him, saying, Get thee hence, and turn thee eastward, and hide thyself by the brook Cherith, that is before Jordan. And it shall be, that thou shalt drink of the brook; and I have commanded the ravens to feed thee there. So he went and did according unto the word of the LORD: for he went and dwelt by the brook Cherith, that is before Jordan. And the ravens brought him bread and flesh in the morning, and bread and flesh in the evening; and he drank of the brook. And it came to pass after a while, that the brook dried up, because there had been no rain in the land. And the word of the LORD came unto him, saying, Arise, get thee to Zarephath, which belongeth to Zidon, and dwell there: behold, I have commanded a widow woman there to sustain thee. So he arose and went to Zarephath. And when he came to the gate of the city, behold, the widow woman was there gathering of sticks: and he called to her, and said, Fetch me, I pray thee, a little water in a vessel, that I may drink. ...

The MotherToBaby Podcast
FASD Discovery and Prevalence

The MotherToBaby Podcast

Play Episode Listen Later Jan 9, 2025 35:18


In this episode, Dr. Kenneth Lyons Jones, one of the pioneers who first identified Fetal Alcohol Spectrum Disorders (FASD) in the United States in 1973, and Dr. Christina Chambers, a renowned epidemiologist who has conducted groundbreaking research on the prevalence of FASD, join host Chris Stallman, CGC, to discuss the discovery of FASD, its common physical and cognitive traits, and its prevalence today. BONUS: Earn continuing education credits for listening to our entire FASD 3-part series. Scroll down to learn more. Resources Mentioned in This Episode: Dr. Kenneth Lyons Jones on the History of Fetal Alcohol Syndrome - FASD  Prevalence of Fetal Alcohol Spectrum Disorders in 4 US Communities | Antenatal Exposures and Child Outcomes | JAMA | JAMA Network  Fetal Alcohol Spectrum Disorders – American Academy of Pediatrics Types of Treatment for FASDs | Fetal Alcohol Spectrum Disorders | CDC Choline supplements in young children with fetal alcohol spectrum disorder have lasting cognitive benefits | National Institute on Alcohol Abuse and Alcoholism (NIAAA)  _______________________________________________________________________________________________________ MotherToBaby: FASD Podcast SCPD4929     PROGRAM DESCRIPTION: This podcast series is intended to reach various audiences, including healthcare professionals, who can use the information presented to inform their practice and their interaction with clients/patients. The podcast episodes will educate participants on 1) the discovery, prevalence, and newest research on the topic of fetal alcohol spectrum disorders (FASDs), 2) CDC's work in addressing prenatal alcohol and other substance use and FASDs, and 3) the experiences of people living with FASDs. OBJECTIVES: After completing this course, the learner will be able to: 1.      Describe Fetal Alcohol Spectrum Disorders (FASDs). 2.      Describe the National Center of Birth Defects and Developmental Disabilities' (NCBDDD) approach to addressing FASDs. 3.      Describe the impact on people who are living with FASDs. 4.      Describe how interprofessional collaboration addresses FASDs. 5. Describe how interprofessional teams can help people living with FASDs transition from pediatric to adult healthcare.   FACULTY/                                                   CREDENTIALS: Laura Bousquet, Family Navigator/Self-Advocate, FASD United Christina Chambers, PhD, MPH, Distinguished Professor of Pediatrics, University of California, San Diego Elizabeth Dang, MPH, Behavioral Scientist, Centers for Disease Control and Prevention Nicholas Deputy, PhD, MPH, Health Scientist, Centers for Disease Control and Prevention Kenneth Jones, MD, Distinguished Professor of Pediatrics, University of California, San Diego  Chris Stallman, MLS, MS, CGC, Director,    MotherToBaby Arizona, University of Arizona  Jennifer Wisdahl, Chief Operating Officer, FASD   United   CE ORIGINATION DATE: CE EXPIRATION DATE:   January 9, 2025 January 9, 2027     URL   https://momtobaby.org/FASDep81youtube   INTENDED AUDIENCE:   Advanced Practice Nurses, Certified Health Educators, Medical Assistants, Licensed Practical/Vocational Nurses, Physicians, Physician Assistants, Registered Nurses, and Social Workers   PREREQUISITES:   Learners will have a basic understanding of what fetal alcohol spectrum disorders are.   FORMAT: This activity is Web on Demand   CONTACT INFORMATION: CDC's CE Accreditation Team has a policy for grievances that is available upon request.   Division of Birth Defects and Infant Disorders cdcinfo@cdc.gov    ACCREDITATION STATEMENTS:     In support of improving patient care, this activity has been planned and implemented by the Centers for Disease Control and Prevention and MotherToBaby. The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team   CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CNE: The Centers for Disease Control and Prevention designates this activity for 0.5 nursing contact hours. CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program. CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 0.5 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. Continuing Competency credits available are 0.5. CDC provider number 98614. DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.    CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies with the exception of Dr. Christina Chambers, PhD, MPH and she wishes to disclose she receives research funding from Amgen, AstraZeneca, GlaxoSmithKline, Janssen Pharmaceuticals, Pfizer, Inc., Regeneron, Hoffman La-Roche-Genentech, Genzyme Sanofi-Aventis, Takeda Pharmaceutical Company Limited, Sanofi, UCB Pharma, USA, Leo Pharma, Sun Pharma Global FZE, Gilead, Novartis, and the Gerber Foundation.  All relevant financial relationships listed for this individual have been mitigated. Content will not include any discussion of the unlabeled use of a product or a product under investigational use. CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity. The Centers for Disease Control and Prevention (CDC) complies with applicable Federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, religion, or sex (including pregnancy, sexual orientation, and gender identity). To learn more visit: https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html. Instructions for Obtaining Continuing Education (CE) To receive continuing education (CE) for SCPD4929 – MotherToBaby: FASD Podcast, please visit CDC TRAIN and search for the course in the Course Catalog using SCPD4929 Follow the steps below by January 9, 2027. Register for and complete the course. Pass the post-assessment at 75 %. Complete the evaluation. Visit Your Learning to access your certificates and transcript.   FEES: No fees are charged for CDC's CE activities.   ______________________________________________________________________ Looking for even more education about FASD? Don't miss a special free Birth Defects Awareness Month webinar January 31, 2025 at 9a PT/12p ET. The webinar will be presented by Dr. Noemi Spinazzi of the American Academy of Pediatrics. It is a free webinar, but advanced registration is required at the following link: https://momtobaby.org/FASDwebinar2025

John Anderson: Conversations
Marilynne Robinson, Pulitzer Prize-Winning Novelist And Author

John Anderson: Conversations

Play Episode Listen Later Jan 7, 2025


Author Marilynne Robinson talks with John about the enduring power of literature, the spiritual depth of Genesis, and the role of faith in shaping civilisation. With grace and wisdom, she explores how ancient texts like the Bible continue to offer moral clarity and insight into human dignity, while lamenting the cultural shift toward superficial modernity. Her reflections remind us that true wisdom lies in understanding our shared history and revering the sacredness of every individual. This conversation offers a rare glimpse into Robinson's deeply held beliefs about democracy, beauty, and the human condition. Thought-provoking and rich in literary references, it challenges us to rethink the narratives of our era and to seek meaning in complexity, compassion, and the timeless pursuit of truth. Marilynne Robinson is an American Pulitzer Prize winning author and novelist. She has written many award-winning books, including Gilead, Housekeeping, Home and Jack. Her latest book is the bestseller Reading Genesis.

The “It” Cast: Real Talk On Sex with Nika Cherrelle
The "It" Cast: Into the Light: Real Talk on the Gender Journey

The “It” Cast: Real Talk On Sex with Nika Cherrelle

Play Episode Listen Later Jan 6, 2025 66:22


Our podcast tonight is in observance of Transgender Day of Remembrance. Mallery Jenna Robinson is an Afro-Caribbean, transgender woman and an advocate for transgender and HIV healthcare in Los Angeles and California. She began acting at 16, starring as Tituba in The Crucible and went on to appear in A Raisin in the Sun and The Scarlet Letter. She taught middle and high school science and history from 2014 to 2019, co-leading the drama club and creating impactful plays. Mallery's work includes producing the award-winning film Two Eyes and starring in Tales of the Trancestors and TransLations. She hosts A Hateful Homicide, a true crime podcast on violence against transgender people, and provides Transgender Empathy Trainings (TET Talks) for organizations like Sony and LA County. Additionally, she's a model, singer, and subject of the documentary The Manifest of Mallery. Mallery's podcast is www.thehatefulhomocide.net. Some resources provided on this podcast: GILEAD - https://www.gileadadvancingaccess.com/ Viiv Healthcare: https://viivhealthcare.com/ Gender affirming care - Plume: https://getplume.co/

Gilead Taylor Podcast
12/24/24 - "What Child is This?" - Christmas at Gilead

Gilead Taylor Podcast

Play Episode Listen Later Dec 24, 2024 39:05


Audio Bible Old Testament Genesis to Job King James Version
2 Samuel (2 Kings) 24: And again the anger of the LORD was kindled against Israel, and he moved David against them to say, Go, number Israel and Judah. ...

Audio Bible Old Testament Genesis to Job King James Version

Play Episode Listen Later Dec 24, 2024 5:00


église AB Lausanne ; KJV 2 Samuel (2 Kings) 24 And again the anger of the LORD was kindled against Israel, and he moved David against them to say, Go, number Israel and Judah. For the king said to Joab the captain of the host, which was with him, Go now through all the tribes of Israel, from Dan even to Beer-sheba, and number ye the people, that I may know the number of the people. And Joab said unto the king, Now the LORD thy God add unto the people, how many soever they be, an hundredfold, and that the eyes of my lord the king may see it: but why doth my lord the king delight in this thing? Notwithstanding the king's word prevailed against Joab, and against the captains of the host. And Joab and the captains of the host went out from the presence of the king, to number the people of Israel. And they passed over Jordan, and pitched in Aroer, on the right side of the city that lieth in the midst of the river of Gad, and toward Jazer: Then they came to Gilead, and to the land of Tahtim-hodshi; and they came to Dan-jaan, and about to Zidon, And came to the strong hold of Tyre, and to all the cities of the Hibites, and of the Canaanites: and they went out to the south of Judah, even to Beer-sheba. So when they had gone through all the land, they came to Jerusalem at the end of nine months and twenty days. And Joab gave up the sum of the number of the people unto the king: and there were in Israel eight hundred thousand valiant men that drew the sword; and the men of Judah were five hundred thousand men. And David's heart smote him after that he had numbered the people. And David said unto the LORD, I have sinned greatly in that I have done: and now, I beseech thee, O LORD, take away the iniquity of thy servant; for I have done very foolishly. ...

Dry Bones Ministries Podcast
The Little Prince Advent Retreat: Theme 4

Dry Bones Ministries Podcast

Play Episode Listen Later Dec 22, 2024 48:37


Join Father Adam for the conclusion of The Little Prince Advent Retreat. The fourth theme is Sight: "One sees clearly only with the heart." Here are a couple quotes that Fr. Adam references in the podcast that are not found in the book: [F]ew value [friendship] because few experience it. And the possibility of going through life without the experience is rooted in that fact which separates Friendship so sharply from both the other loves [affection and eros]. Friendship is…the least natural of loves; the least instinctive, organic, biological, gregarious and necessary. …Without Eros none of us would have been begotten and without Affection none of us would have been reared; but we can live and breed without Friendship. (CS Lewis, The Four Loves, 58)  4 Behold, you are beautiful, my love, behold, you are beautiful! Your eyes are doves behind your veil. Your hair is like a flock of goats, moving down the slopes of Gilead. 2 Your teeth are like a flock of shorn ewes that have come up from the washing, all of which bear twins, and not one among them is bereaved. 3 Your lips are like a scarlet thread, and your mouth is lovely. Your cheeks are like halves of a pomegranate behind your veil. 4 Your neck is like the tower of David, built for an arsenal, whereon hang a thousand bucklers, all of them shields of warriors. (Song of Songs 4:1-4)[W]hat the Church teaches affects even the things already in the landscape, the things of ordinary experience. It is like a physical landscape at sunrise: it is not that you see the same things that you saw before and now find yourself seeing the sun as well. You see everything sun-bathed. Similarly it is not a case of seeing the same universe as other people and then seeing God over and above. For God is at the center of the being of everything whatsoever. If we would see the Universe aright, we must see it God-bathed. (Frank Sheed, Theology and Sanity, 28)

Gilead Taylor Podcast
12/22/24 - "The Power of a Memory" - Christmas at Gilead

Gilead Taylor Podcast

Play Episode Listen Later Dec 22, 2024 38:06


How Women Inspire: Invest, Lead, Give
Embracing Authenticity and Overcoming Self-Doubt with Liz Sklar, Director at Stand & Deliver and Actress [Replay]

How Women Inspire: Invest, Lead, Give

Play Episode Listen Later Dec 18, 2024 31:12


Are you a woman in leadership struggling to manage stress and are not feeling like your authentic self? In this episode of How Women Inspire, Liz Sklar, Director of Stand and Deliver and actress, shares her journey from stage to C-suite and how she helps leaders find their authentic voice and communicate powerfully. Liz and Julie discuss the importance of managing stress, setting boundaries, and embracing your personal values to become a more impactful and authentic leader. They also explore the power of storytelling, emotional resilience, and overcoming self-doubt for women in leadership.In this episode of How Women Inspire Podcast, Liz Sklar is sharing the importance of managing stress and setting boundaries  and actionable steps you can take right now to lead with authenticity and sincerity.In her work with clients including Genentech, Gilead, Twilio, Google, IVP, CZI, Waymo, and the Cartier Women's Initiative, Liz's work has crossed industries from pharma to finance and frequently focuses on leaders in the innovation economy. She is especially inspired by female entrepreneurs and executives and is invested in empowering them to harness their innate power and wisdom to further their careers and expand their missions. Liz has acted professionally in both film and theater, including leading roles at premier regional theaters such as California Shakespeare Festival and American Conservatory Theatre.Some of the talking points Julie and Liz go over in this episode include:How Liz's experience in theatre informs her leadership coaching in the corporate world.Emphasizing the value of finding and showcasing one's authentic self.Managing stress and influencing without authority in the workplace.Encouraging and supporting women leaders through empathy and public speaking.Thank you for listening! If you enjoyed this episode, take a screenshot of the episode to post in your stories and tag me!  And don't forget to follow, rate, and review the podcast and tell me your key takeaways!Learn more about How Women Inspire at https://www.howwomenlead.com/podcast CONNECT WITH LIZ SKLAR:LinkedInWebsiteStand & DeliverCONNECT WITH JULIE CASTRO ABRAMS:LinkedIn - JulieHow Women LeadHow Women InvestHow Women GiveInstagram - HWLLinkedIn - HWLFacebook - HWL

Gilead Taylor Podcast
12/15/24 - "To Hell with Hesitation" - Christmas at Gilead

Gilead Taylor Podcast

Play Episode Listen Later Dec 15, 2024 44:31


24 horas
El fármaco lenacapavir contra el VIH: avance médico más importante de 2024 para la revista Science

24 horas

Play Episode Listen Later Dec 12, 2024 6:47


La revista científica Science ha escogido el lenacapavir como el avance médico más importante de este año. Se trata de un fármaco inyectable que previene -con una eficacia cercana al cien por cien- infectarse de VIH durante seis meses. La publicación resalta su potencial para reducir drásticamente las infecciones en poblaciones de alto riesgo pero también recuerda que su implementación global dependerá de su acceso, los acuerdos de fabricación y una infraestructura sanitaria robusta. Actualmente, la patente la tiene la farmacéutica Gilead y el valor del fármaco es de 40.000 dólares. Un estudio de Oxford reveló que, si se liberaba la patente, se podía fabricar un genérico por tan solo 40 dólares.El doctor Javier Martínez-Picado, es investigador ICREA en IrsiCaixa explica en 24 horas de RNE que el lenacapavir es el primero de una nueva clase de fármacos que "interactúa con el virus de forma diferente". El lenacapavir, cuenta el doctor, desestructura la cápsula en la que viaja el material genético del virus del VIH y evita que este material genético llegue al núcleo de las células: "Esto es tan novedoso que se puede conseguir con cantidades ínfimas del fármaco. Esto permite que tenga tanta acción y que se haya podido formular en formato inyectable", resume. Martínez-Picado explica que el medicamento ha tardado unos 18 años en desarrollarse: "Probablemente se pueda utilizar en otros formatos, en otros virus. Va a permitir ser una herramienta de prevención: son dos inyecciones cada seis meses. Al mismo tiempo, es un fármaco que intentará posicionarse como tratamiento de personas ya infectadas". Una vez que el fármaco está en el mercado, explica el investigador, suele haber negociaciones entre farmacéuticas y distintos países: "Se suelen llegar a acuerdos en los que no todos los países el precio termina siendo el mismo. Es un medicamento caro pero estoy seguro de que irá abaratándose y es posible que aparezcan moléculas parecidas, que puedan competir con el lenacapavir. Pero es un avance realmente importante".Escuchar audio

Pharma and BioTech Daily
Pharma and Biotech Daily: Latest Updates in the World of Drug Development and Deal Making

Pharma and BioTech Daily

Play Episode Listen Later Dec 12, 2024 1:42


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.J&J and Legend have released new Phase III data for their drug Carvykti, showing nearly 90% of patients had no detectable cancer cells after treatment. This data could help them fend off competition from emerging CAR T therapies like Gilead and Arcellx's Anito-cel. Biontech also has promising breast cancer data for their drug BNT327, while Moderna's RSV vaccines are facing safety concerns. Meanwhile, there is pushback against IRA's controversial 'pill penalty'. Opportunities to become a US Pharmacopeia expert volunteer are available. In the biotech industry, Acelyrin terminated its drug Izokibep after failed Phase IIB/III data, Cellectar downsized by 60%, and M&A spending has been small this year.Pharma dealmaking in 2024 has mostly stayed under $5 billion, with the exception of Novo Holdings' acquisition of Catalent for $16.5 billion. The proposed EPIC Act, which aims to give small molecule drugs the same protection against price negotiation as biologics, faces challenges due to concerns over balancing the federal budget. The biotech IPO class of 2024 has struggled, with many companies tumbling from their original offer price after going public. Novo and Catalent's deal has received EU approval, Lilly is investing $3 billion in a Wisconsin site, and GSK is making agreements to further their presence in neurology. Carisma Therapeutics is cutting staff and reprioritizing their pipeline, while Relmada is exploring strategic alternatives after a failed asset in depression. Cellectar is downsizing by 60% as they explore options for their cancer drug.

BioSpace
Highlights From ASH, Lilly and Novo's Manufacturing Boon, Momentum in Neuro, More

BioSpace

Play Episode Listen Later Dec 11, 2024 10:00


This week, GSK and Gilead and Arcellx presented key data at the American Society of Hematology (ASH) annual meeting as they vie for a competitive advantage in multiple myeloma. Meanwhile, Vertex unveiled positive long-term data for its CRISPR Therapeutics–partnered gene therapy Casgevy in sickle cell disease—results BMO Capital Markets analysts said should help Casgevy keep its edge over bluebird bio's Lyfgenia. On that note, Casgevy and Lyfgenia have a new outcomes-based payment model after the Centers for Medicare and Medicaid Service (CMS) said both companies have agreed to participate in a voluntary program to improve access to the gene therapies. Speaking of access, Eli Lilly and Novo Nordisk both announced significant manufacturing investments aimed at shoring up production of their diabetes and weight loss blockbusters tirzepatide and semaglutide. And in related news, the European Commission gave its blessing to Novo Holdings' controversial acquisition of contract manufacturing firm Catalent. Elsewhere, AbbVie got a much-needed win for Cerevel-acquired Parkinson's disease therapy tavapadon—a month after the deal's cornerstone asset emraclidine failed in schizophrenia—while uniQure announced it has aligned with the FDA on “key elements” of the accelerated approval pathway for its investigational gene therapy for Huntington's, AMT-130.

Lab to Startup
Partnering to accelerate therapeutics: A primer on forming alliances and their management

Lab to Startup

Play Episode Listen Later Dec 10, 2024 50:40


Monica Rosoff, the founder and CEO of LBBAL™ Alianza. Prior to launching Alianza, Monica was a partnering executive with roles of increasing seniority at Genentech, Gilead, Kite and Exelixis. Over the course of over two decades, she had the opportunity to lead and participate in a wide diversity of deals, negotiations, diligence exercises, alliances, technology transfers, M&A integrations, dispute resolution negotiations, amendments and terminations–at all stages of the drug development and commercialization lifecycle and in multiple therapeutic areas. Dr. Rosoff earned a doctorate in Pharmacology from the University of Washington and conducted her postdoctoral work at Stanford. We talked about lessons learned from her experiences in alliance management, especially for early stage startups.  Shownotes Monica Rosoff https://lbbalalianza.com/ Monica's entry into alliance management Principles that guide a good partnership: What's best for the patient? Find synergies, timing and motivations Who to approach at a big pharma when identifying a partner? Evaluating motivations of a big pharma: Get specific Building trust Performing due diligence-How? Power dynamics: How to deal with a big partner when you have a power imbalance? Role of lawyers Communicating failures Have a list of “To-dont's” as opposed to “To-do” list Conflicts might be important Repeating problems: Lessons learned How to prepare for unexpected changes at big companies? Conflict resolution: What to pick fights on? Allocating resources

Gilead Taylor Podcast
12/8/24 - "Letting Go of Stuff" - Christmas at Gilead

Gilead Taylor Podcast

Play Episode Listen Later Dec 8, 2024 52:13


ESC TV Today – Your Cardiovascular News
Season 3 - Ep.6: Hypertensive disorders during pregnancy - Depression and heart disease

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Dec 5, 2024 26:05


ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Hypertensive disorders during pregnancy Depression and heart disease Mythbusters: "The French Paradox" Host: Perry Elliott Guests: Carlos Aguiar, Martha Gulati, Hector Bueno Want to watch that episode? Go to: https://esc365.escardio.org/event/1796 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Martha Gulati, Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Hector Bueno has declared to have potential conflicts of interest to report: research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Pharma and BioTech Daily
The Latest in Pharma and Biotech: Lilly's Weight Loss Victory and Industry Updates

Pharma and BioTech Daily

Play Episode Listen Later Dec 5, 2024 1:36


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lilly emerged victorious in a head-to-head weight loss battle against NovoPlus, showcasing the effectiveness of tirzepatide over semaglutide. This victory has highlighted the potential of tirzepatide in promoting weight loss, with results aligning with real-world studies. Meanwhile, Amylin has garnered attention in the weight loss sphere ahead of Novo's cagrisema readout, with industry anticipation for the phase III results. Amylin analogs are seen as a promising alternative to GLP-1 receptor agonists, offering potentially higher-quality weight loss with improved tolerability. Additionally, GSK has turned to China for another potential ADC deal worth over $1 billion with Dualitybio.The Trump administration's impact on the biopharma industry is expected to be mixed, with potential promotion of M&A activity but concerns about vaccine sales due to controversial picks. Intra-Cellular is seeking FDA approval for Caplyta in major depressive disorder, which could generate significant sales. Sarepta Therapeutics, known for regulatory success, has made a significant deal with Arrowhead Pharmaceuticals for RNA-based medicines. Other news includes Lilly's victory over Novo in a weight loss study, anticipation for Novo's phase III Cagrisema readout, Novartis' deal with PTC for Huntington's disease, and more. Takeda is investing in Keros' blood cancer anemia drug, Roche partners with Cour in an autoimmune deal, and Gilead is planning an ADC comeback with a potential license agreement. Alligator Bioscience has cut staff due to capital constraints.

Gilead Taylor Podcast
12/4/24 - "A Moment of Surrender" - Christmas at Gilead

Gilead Taylor Podcast

Play Episode Listen Later Dec 4, 2024 40:07


Sand Harbor Sermons
Genesis 31:1-55

Sand Harbor Sermons

Play Episode Listen Later Dec 4, 2024 37:02


Jacob Flees from Laban 31.1 Now Jacob heard that the sons of Laban were saying, “Jacob has taken all that was our father's, and from what was our father's he has gained all this wealth.” 2 And Jacob saw that Laban did not regard him with favor as before. 3 Then the Lord said to Jacob, “Return to the land of your fathers and to your kindred, and I will be with you.” 4 So Jacob sent and called Rachel and Leah into the field where his flock was 5 and said to them, “I see that your father does not regard me with favor as he did before. But the God of my father has been with me. 6 You know that I have served your father with all my strength, 7 yet your father has cheated me and changed my wages ten times. But God did not permit him to harm me. 8 If he said, ‘The spotted shall be your wages,' then all the flock bore spotted; and if he said, ‘The striped shall be your wages,' then all the flock bore striped. 9 Thus God has taken away the livestock of your father and given them to me. 10 In the breeding season of the flock I lifted up my eyes and saw in a dream that the goats that mated with the flock were striped, spotted, and mottled. 11 Then the angel of God said to me in the dream, ‘Jacob,' and I said, ‘Here I am!' 12 And he said, ‘Lift up your eyes and see, all the goats that mate with the flock are striped, spotted, and mottled, for I have seen all that Laban is doing to you. 13 I am the God of Bethel, where you anointed a pillar and made a vow to me. Now arise, go out from this land and return to the land of your kindred.'” 14 Then Rachel and Leah answered and said to him, “Is there any portion or inheritance left to us in our father's house? 15 Are we not regarded by him as foreigners? For he has sold us, and he has indeed devoured our money. 16 All the wealth that God has taken away from our father belongs to us and to our children. Now then, whatever God has said to you, do.” 17 So Jacob arose and set his sons and his wives on camels. 18 He drove away all his livestock, all his property that he had gained, the livestock in his possession that he had acquired in Paddan-aram, to go to the land of Canaan to his father Isaac. 19 Laban had gone to shear his sheep, and Rachel stole her father's household gods. 20 And Jacob tricked Laban the Aramean, by not telling him that he intended to flee. 21 He fled with all that he had and arose and crossed the Euphrates, and set his face toward the hill country of Gilead. 22 When it was told Laban on the third day that Jacob had fled, 23 he took his kinsmen with him and pursued him for seven days and followed close after him into the hill country of Gilead. 24 But God came to Laban the Aramean in a dream by night and said to him, “Be careful not to say anything to Jacob, either good or bad.” 25 And Laban overtook Jacob. Now Jacob had pitched his tent in the hill country, and Laban with his kinsmen pitched tents in the hill country of Gilead.26 And Laban said to Jacob, “What have you done, that you have tricked me and driven away my daughters like captives of the sword? 27 Why did you flee secretly and trick me, and did not tell me, so that I might have sent you away with mirth and songs, with tambourine and lyre? 28 And why did you not permit me to kiss my sons and my daughters farewell? Now you have done foolishly. 29 It is in my power to do you harm. But the God of your father spoke to me last night, saying, ‘Be careful not to say anything to Jacob, either good or bad.' 30 And now you have gone away because you longed greatly for your father's house, but why did you steal my gods?” 31 Jacob answered and said to Laban, “Because I was afraid, for I thought that you would take your daughters from me by force. 32 Anyone with whom you find your gods shall not live. In the presence of our kinsmen point out what I have that is yours, and take it.” Now Jacob did not know that Rachel had stolen them.

Pharma and BioTech Daily
Pharma and Biotech Daily: The Latest Deals and Developments in the Industry

Pharma and BioTech Daily

Play Episode Listen Later Dec 4, 2024 1:14


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Takeda, Roche, and Gilead have recently made significant deals in the pharmaceutical industry. Takeda's investment of up to $1.3 billion in Keros' blood cancer anemia drug is making waves, potentially challenging Bristol Myers Squibb. Roche has joined forces with Cour in a deal focused on autoimmune diseases, valued at over $900 million. Meanwhile, Gilead is reentering the ADC space with a potential $415 million license agreement.In other news, Intra-Cellular is seeking approval for Caplyta in major depressive disorder, a move that could result in $1 billion in sales. Unfortunately, Alligator has been forced to reduce its staff by 70% due to capital constraints. On a brighter note, Biocon has received FDA approval for a biosimilar to J&J's Stelara, and Applied Therapeutics is making strides in the fight against deadly brain cancer.However, Bluebird's gene therapy Skysona is currently under FDA safety probe for hematologic malignancies, raising concerns within the industry. Despite this setback, the pharmaceutical industry as a whole continues to see growth and innovation on multiple fronts.

Priorité santé
Les traitements du VIH: accès et nouveautés

Priorité santé

Play Episode Listen Later Dec 2, 2024 48:30


Problème majeur de santé publique, le VIH est une infection attaquant le système immunitaire de l'organisme. Fin 2022, l'OMS estimait que 39 millions de personnes vivaient avec le VIH, dans le monde, dont plus des deux-tiers dans la région africaine. Or, le VIH peut être traité et évité grâce au traitement antirétroviral. Si aujourd'hui, aucun médicament ne permet d'éliminer complètement le VIH de l'organisme, un nouveau traitement innovant qui repose sur 2 injections annuelles pour un coût de 40.000 $, le Lénacapavir est jugé extrêmement prometteur.  Suite à la demande de l'ONUSIDA, son fabricant, le laboratoire GILEAD a signé en octobre 2024 un accord de licence avec 6 génériqueurs pour, à terme, espérer le rendre accessible dans 120 pays.En quoi consistent ces traitements ? Qu'en est-il de l'accès à ces traitements par les populations les plus vulnérables ? Peut-on encore envisager la fin de l'épidémie en 2030, objectif fixé par l'OMS, le Fonds mondial et l'ONUSIDA ? Pr Jade Ghosn, médecin infectiologue, responsable du Centre d'Information, de Dépistage et de Diagnostic du VIH et des IST, à l'Hôpital Bichat-Claude Bernard, APHP, à Paris. Professeur des Universités en Maladies Infectieuses à la Faculté de Médecine de l'Université Paris Cité et médecin des Hôpitaux de Paris. Président du Comité de Coordination Régionale de la lutte contre les VIH et les Infections Sexuellement Transmissibles pour l'Île-de-France Nord (COREVIH Île-de-France Nord) Dr Leopold Zekeng, directeur Pays et représentant de l'ONUSIDA au Nigeria Rostand, activiste d'une organisation communautaire au Cameroun, membre des réseaux Coalition PLUS, plateforme d'organisations communautaires de lutte contre le VIH. Membre de la task force pour la reconnaissance des métiers de la paire-éducation.► En fin d'émission, nous faisons un point sur les travaux conduits par l'Inserm, l'Université Grenoble Alpes et le CHU Grenoble-Alpes, au Pérou, dans la ville la plus haute du monde, Rinconada (5 300 m), sur l'impact du manque d'oxygène sur le corps. Interview de Samuel Vergès, directeur de recherche INSERM à l'Université Grenoble Alpes, responsable du programme de recherche Expedition 5300.Programmation musicale :►Senny Camara – Yeuk ► Gabi Hartmann – Take a swing at the moon.  

Priorité santé
Les traitements du VIH: accès et nouveautés

Priorité santé

Play Episode Listen Later Dec 2, 2024 48:30


Problème majeur de santé publique, le VIH est une infection attaquant le système immunitaire de l'organisme. Fin 2022, l'OMS estimait que 39 millions de personnes vivaient avec le VIH, dans le monde, dont plus des deux-tiers dans la région africaine. Or, le VIH peut être traité et évité grâce au traitement antirétroviral. Si aujourd'hui, aucun médicament ne permet d'éliminer complètement le VIH de l'organisme, un nouveau traitement innovant qui repose sur 2 injections annuelles pour un coût de 40.000 $, le Lénacapavir est jugé extrêmement prometteur.  Suite à la demande de l'ONUSIDA, son fabricant, le laboratoire GILEAD a signé en octobre 2024 un accord de licence avec 6 génériqueurs pour, à terme, espérer le rendre accessible dans 120 pays.En quoi consistent ces traitements ? Qu'en est-il de l'accès à ces traitements par les populations les plus vulnérables ? Peut-on encore envisager la fin de l'épidémie en 2030, objectif fixé par l'OMS, le Fonds mondial et l'ONUSIDA ? Pr Jade Ghosn, médecin infectiologue, responsable du Centre d'Information, de Dépistage et de Diagnostic du VIH et des IST, à l'Hôpital Bichat-Claude Bernard, APHP, à Paris. Professeur des Universités en Maladies Infectieuses à la Faculté de Médecine de l'Université Paris Cité et médecin des Hôpitaux de Paris. Président du Comité de Coordination Régionale de la lutte contre les VIH et les Infections Sexuellement Transmissibles pour l'Île-de-France Nord (COREVIH Île-de-France Nord) Dr Leopold Zekeng, directeur Pays et représentant de l'ONUSIDA au Nigeria Rostand, activiste d'une organisation communautaire au Cameroun, membre des réseaux Coalition PLUS, plateforme d'organisations communautaires de lutte contre le VIH. Membre de la task force pour la reconnaissance des métiers de la paire-éducation.► En fin d'émission, nous faisons un point sur les travaux conduits par l'Inserm, l'Université Grenoble Alpes et le CHU Grenoble-Alpes, au Pérou, dans la ville la plus haute du monde, Rinconada (5 300 m), sur l'impact du manque d'oxygène sur le corps. Interview de Samuel Vergès, directeur de recherche INSERM à l'Université Grenoble Alpes, responsable du programme de recherche Expedition 5300.Programmation musicale :►Senny Camara – Yeuk ► Gabi Hartmann – Take a swing at the moon.  

Gilead Taylor Podcast
12/1/24 - "When It's Difficult to Obey" - Christmas at Gilead

Gilead Taylor Podcast

Play Episode Listen Later Dec 1, 2024 45:57


Common Prayer Daily
Saturday - Proper 29

Common Prayer Daily

Play Episode Listen Later Nov 30, 2024 17:38


Support Common Prayer Daily @ PatreonVisit our Website for more www.commonprayerdaily.com_______________Opening Words:“Let the words of my mouth and the meditation of my heart be acceptable in your sight, O Lord, my rock and my redeemer.”Psalm 19:14 (ESV) Confession:Let us humbly confess our sins unto Almighty God. Most merciful God, we confess that we have sinned against you in thought, word, and deed, by what we have done, and by what we have left undone. We have not loved you with our whole heart; we have not loved our neighbors as ourselves. We are truly sorry and we humbly repent. For the sake of your Son Jesus Christ, have mercy on us and forgive us; that we may delight in your will, and walk in your ways, to the glory of your Name. Amen. Almighty God have mercy on you, forgive you all your sins through our Lord Jesus Christ, strengthen you in all goodness, and by the power of the Holy Spirit keep you in eternal life. Amen. The InvitatoryLord, open our lips.And our mouth shall proclaim your praise.Glory to the Father, and to the Son, and to the Holy Spirit:as it was in the beginning, is now, and will be forever. Amen. Venite (Psalm 95:1-7)Worship the Lord in the beauty of holiness: Come let us adore him. Come, let us sing to the Lord; * let us shout for joy to the Rock of our salvation.Let us come before his presence with thanksgiving * and raise a loud shout to him with psalms.For the Lord is a great God, * and a great King above all gods.In his hand are the caverns of the earth, * and the heights of the hills are his also.The sea is his, for he made it, * and his hands have molded the dry land.Come, let us bow down, and bend the knee, * and kneel before the Lord our Maker.For he is our God, and we are the people of his pasture and the sheep of his hand. *Oh, that today you would hearken to his voice! Worship the Lord in the beauty of holiness: Come let us adore him. The PsalterPsalm 137Super flumina1By the waters of Babylon we sat down and wept, *when we remembered you, O Zion.2As for our harps, we hung them up *on the trees in the midst of that land.3For those who led us away captive asked us for a song,and our oppressors called for mirth: *“Sing us one of the songs of Zion.”4How shall we sing the Lord's song *upon an alien soil?5If I forget you, O Jerusalem, *let my right hand forget its skill.6Let my tongue cleave to the roof of my mouthif I do not remember you, *if I do not set Jerusalem above my highest joy.Psalm 144Benedictus Dominus1Blessed be the Lord my rock! *who trains my hands to fight and my fingers to battle;2My help and my fortress, my stronghold and my deliverer, *my shield in whom I trust,who subdues the peoples under me.3O Lord, what are we that you should care for us? *mere mortals that you should think of us?4We are like a puff of wind; *our days are like a passing shadow.5Bow your heavens, O Lord, and come down; *touch the mountains, and they shall smoke.6Hurl the lightning and scatter them; *shoot out your arrows and rout them.7Stretch out your hand from on high; *rescue me and deliver me from the great waters,from the hand of foreign peoples,8Whose mouths speak deceitfully *and whose right hand is raised in falsehood.9O God, I will sing to you a new song; *I will play to you on a ten-stringed lyre.10You give victory to kings *and have rescued David your servant.11Rescue me from the hurtful sword *and deliver me from the hand of foreign peoples,12Whose mouths speak deceitfully *and whose right hand is raised in falsehood.13May our sons be like plants well nurtured from their youth, *and our daughters like sculptured corners of a palace.14May our barns be filled to overflowing with all manner of crops; *may the flocks in our pastures increase by thousands and tens of thousands;may our cattle be fat and sleek.15May there be no breaching of the walls, no going into exile, *no wailing in the public squares.16Happy are the people of whom this is so! *happy are the people whose God is the Lord! Glory to the Father, and to the Son, and to the Holy Spirit: *as it was in the beginning, is now, and will be forever. Amen. LessonsMicah 7:11-20English Standard VersionA day for the building of your walls!    In that day the boundary shall be far extended.In that day they will come to you,    from Assyria and the cities of Egypt,and from Egypt to the River,    from sea to sea and from mountain to mountain.But the earth will be desolate    because of its inhabitants,    for the fruit of their deeds.Shepherd your people with your staff,    the flock of your inheritance,who dwell alone in a forest    in the midst of a garden land;let them graze in Bashan and Gilead    as in the days of old.As in the days when you came out of the land of Egypt,    I will show them marvelous things.The nations shall see and be ashamed of all their might;they shall lay their hands on their mouths;    their ears shall be deaf;they shall lick the dust like a serpent,    like the crawling things of the earth;they shall come trembling out of their strongholds;    they shall turn in dread to the Lord our God,    and they shall be in fear of you.Who is a God like you, pardoning iniquity    and passing over transgression    for the remnant of his inheritance?He does not retain his anger forever,    because he delights in steadfast love.He will again have compassion on us;    he will tread our iniquities underfoot.You will cast all our sins    into the depths of the sea.You will show faithfulness to Jacob    and steadfast love to Abraham,as you have sworn to our fathers    from the days of old.1 Peter 4:7-19English Standard VersionThe end of all things is at hand; therefore be self-controlled and sober-minded for the sake of your prayers. Above all, keep loving one another earnestly, since love covers a multitude of sins. Show hospitality to one another without grumbling. As each has received a gift, use it to serve one another, as good stewards of God's varied grace: whoever speaks, as one who speaks oracles of God; whoever serves, as one who serves by the strength that God supplies—in order that in everything God may be glorified through Jesus Christ. To him belong glory and dominion forever and ever. Amen.Beloved, do not be surprised at the fiery trial when it comes upon you to test you, as though something strange were happening to you. But rejoice insofar as you share Christ's sufferings, that you may also rejoice and be glad when his glory is revealed. If you are insulted for the name of Christ, you are blessed, because the Spirit of glory and of God rests upon you. But let none of you suffer as a murderer or a thief or an evildoer or as a meddler. Yet if anyone suffers as a Christian, let him not be ashamed, but let him glorify God in that name. For it is time for judgment to begin at the household of God; and if it begins with us, what will be the outcome for those who do not obey the gospel of God? And“If the righteous is scarcely saved,    what will become of the ungodly and the sinner?”Therefore let those who suffer according to God's will entrust their souls to a faithful Creator while doing good. The Word of the Lord.Thanks Be To God. Benedictus (The Song of Zechariah)Blessed be the Lord, the God of Israel; * he has come to his people and set them free.He has raised up for us a mighty savior, * born of the house of his servant David.Through his holy prophets he promised of old, that he would save us from our enemies, * from the hands of all who hate us. He promised to show mercy to our fathers * and to remember his holy covenant. This was the oath he swore to our father Abraham, * to set us free from the hands of our enemies, Free to worship him without fear, * holy and righteous in his sight all the days of our life.You, my child, shall be called the prophet of the Most High, * for you will go before the Lord to prepare his way, To give his people knowledge of salvation * by the forgiveness of their sins.In the tender compassion of our God * the dawn from on high shall break upon us, To shine on those who dwell in darkness and the shadow of death, * and to guide our feet into the way of peace.Glory to the Father, and to the Son, and to the Holy Spirit:as it was in the beginning, is now, and will be for ever. Amen. The Apostles CreedI believe in God, the Father almighty, creator of heaven and earth.I believe in Jesus Christ, his only Son, our Lord. He was conceived by the Holy Spirit and born of the Virgin Mary. He suffered under Pontius Pilate, was crucified, died, and was buried. He descended to the dead. On the third day he rose again. He ascended into heaven, and is seated at the right hand of the Father. He will come again to judge the living and the dead.I believe in the Holy Spirit, the holy catholic Church, the communion of saints, the forgiveness of sins, the resurrection of the body, and the life everlasting. Amen. The PrayersLord, have mercy.Christ, have mercyLord, have mercyOur Father, who art in heaven, hallowed be thy Name,